Strategies for identifying familial hypercholesterolaemia in non‐specialist clinical settings
Referencias
Additional references
Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. American Journal of Epidemiology 2004;160(5):407‐20.
Baumer JH, Sheild JPH. Hypercholesterolaemia in children guidelines review. Archives of Disease in Childhood Disease. Education & Practice Edition 2009;94:84‐6.
Bell DA, Hooper AJ, Bender R, McMahon J, Edwards G, van Bockmeer FM, et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Annals of Clinical Biochemistry 2012;49(Pt 6):534‐7.
Bell DA, Bender R, Hooper AJ, McMahon J, Edwards G, van Bockxmeer FM, et al. Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. Clinica Chimica Acta 2013;422:21‐5.
Bell DA, Hooper AJ, Edwards G, Southwell L, Pang J, van Bockxmeer FM, et al. Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis 2104;234(2):469‐72.
Benn M, Watts GF, Tybjaerg‐Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol‐lowering medication. Journal of Clinical Endocrinology and Metabolism 2012;97(11):3956‐64.
Besseling J, Reitsma JB, Hovingh GK, Hutten A. Predicting the presence of a mutation resulting in familial hypercholesterolemia‐development of a prediction model in a cohort of 64,000 subjects. Circulation 2004;130:S2.
Defesche JC, Lansberg PJ, Umans‐Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with familial hypercholesterolaemia. Seminars in Vascular Medicine 2004;4(1):59‐65.
Demott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M, et al. Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008.
Foody JM. Familial Hypercholesterolaemia: an under‐recognized but significant concern in cardiology practice. Clinical Cardiology 2014;37(2):119‐25.
Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolaemia: a scientific statement from the American Heart Association. Circulation 2015;132(22):2167‐92.
Goldberg A, Hopkins MD, Toth P, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Clinical Lipidology 2011;5(3 Suppl):133‐40.
Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolaemia. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill, 1995.
Gray J, Jaiyeola A, Whiting M, Modell M, Wierzbicki AS. Identifying patients with familial hypercholesterolaemia in primary care: an informatics‐based approach in one primary care centre. Heart 2008;94(6):754‐8.
Green P, Neely D, Humphries SE, Saunders SE, Gray V, Gordon L, et al. Improving detection of familial hypercholesterolaemia in primary care using electronic audit and nurse‐led clinics. Journal of Evaluation in Clinical Practice 2015;22(3):341‐8.
Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342(8883):1317‐22.
Haase A, Goldberg AC. Identification of people with heterozygous familial hypercholesterolemia. Current Opinion in Lipidology 2012;23(4):282‐9.
Harada‐Shiba M, Arai H, Okamura T, Yokote K, Oikawa S, Nohara A, et al. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. Journal of Arthritis and Atherosclerosis 2012;19(11):1019‐26.
Haralambos K, Whatlet SD, Edwards R, Gingell R, Townsend D, Ashfield‐Watt P. Clinical experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 2016;240(1):190‐6.
Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, et al. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. Journal of Athersclerosis and Thrombosis 2002;9(1):1‐27.
Hewitson P, Glasziou PP, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001216.pub2]
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JP, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2010]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JP, Altman DG, Sterne JA, editor(s) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Deeks JJ, Higgins JP, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Kirke AB, Barbour RA, Burrows S, Bell DA, Vickery AW, Emery J, et al. Systematic detection of familial hypercholesterolaemia in primary health care: a community based prospective study of three methods. Heart, Lung and Circulation 2015;24(3):250‐6.
Knowles JW, Stone NK, Ballantyne CM. Familial hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: myths, oversimplification, and misinterpretation versus facts. American Journal of Cardiology 2015;116(3):481‐4.
Marks D, Thorogood M, Neil AW, Humphries SE. A review on the diagnosis, natural history and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168(1):1‐14.
Michie S, Johnston M. Changing clinical behaviour by making guidelines specific. BMJ 2004;328(7435):343‐5.
Nherera LD, Marks D, Minhas, R, Thorogood M, Humphries SE. Probabilistic cost‐effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011;97(14):1175‐81.
National Institute for Health and Care Excellence. Familial hypercholesterolaemia: identification and management. Clinical guideline 71. www.nice.org.uk/Guidance/CG71 (accessed on 5 January 2017).
National Institute for Health and Care Excellence. Familial hypercholesterolaemia: identification and management: update clinical guideline 71. www.nice.org.uk/guidance/cg71 (accessed 19 December 2017).
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal 2013;34(45):3478–90.
Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R. Identification and management of familial hypercholesterolaemia: what does it mean to primary care?. British Journal of General Practice 2009;59(567):773‐8.
Qureshi N, Weng SF, Tranter J, El‐Kadiki A, Kai J. Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study. BMJ Open 2016;6(5):1‐5.
Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series design in health technology assessment: lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care 2016;19(4):613‐23.
Reeves BC, Deeks JJ, Higgins JP, Wells GA, on behalf of the Cochrane Non‐Randomised Studies Methods Group. Chapter 13: Including non‐randomised studies. In: Higgins JP, Greem S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration.
Reeves MM, Terranova CO, Erickson JM, Job JR, Brookes DSK, McCarthy N, et al. Living well after breast cancer randomized controlled trial protocol: evaluating a telephone‐delivered weight loss intervention versus usual care in women following treatment for breast cancer. BioMed Cancer 2016;16(1):1‐17.
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wilkund O, et al. ESC/EAS Guidelines for management of dyslipidaemias. European Heart Journal 2011;32:1769‐1818.
Reiner Z. A comparison of European and US guidelines for familial hypercholesterolaemia. Current Opinion in Lipidology 2015;26(3):215‐20.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Robinson JG, Goldberg AC, National Lipid Association Expert Panel on Familial Hypercholesterolemia. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011;5(3 Suppl):S18‐29.
Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH on behalf of the CA and RMG and the CSMG. Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303(6807):893.
StataCorp LP. Stata Statistical Software. Version Release 14. College Station, TX: StataCorp LP, 2015.
Sterne JA, Higgins JP, Reeves BC on behalf of the development group for ROBINS‐1. ROBINS‐1: a tool for assessing Risk of Bias in Non‐randomized studies of Interventions (Version 7). www.riskofbias.info (accessed 05 January 2017).
Sullivan D, Watts G, Hamilton I. Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia. Cardiac Society of Australia and New Zealand2013.
Troeung L, Arnold‐Reed D, Ping‐Delfos WC, Watts GF, Pang J, Lugonja M, et al. A new electronic screening tool for identifying risk of familial hypercholesterolaemia in general practice. Heart 2016;102(11):855‐61.
Vallejo‐Vaz AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, Kastelein JJ, Mata P, et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis 2015;243(1):257‐9.
van Maarle MC, Stouthard ME, Bonsel GJ. Risk perception of participants in a family‐based genetic screening program on familial hypercholesterolemia. American Journal of Medical Genetics. Part A 2003;116A(2):136‐43.
Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child‐parent familial hypercholesterolemia screening in primary care. New England Journal of Medicine 2016;376(5):1628‐37.
Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton‐Craig I, Clifton PM, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atherosclerosis. Supplements 2011;12(2):221‐63.
Watts GF, Pang J, Santos RD. Europe aspires to set the record straight on familial hypercholesterolaemia. Atherosclerosis 2015;241:769‐71.
Wiegman A, Gidding SS, Watts GF, Chapman JC, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal 2015;36(36):2425‐37.
Weng SF, Kai J, Neil HA, Humphries SE, Qureshi N. Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 2015;238(2):336‐43.
Medis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. World Health Organization. www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/. World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization, 2011 (accessed on 21 December 2016).
Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. American Journal of Cardiology 1993;72(2):171‐6.
